Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: MSNBC.com
Novo Nordisk said Wednesday that demand for itsWegovy pillBy Jan. 23 —less than three weeks after it became availableRoughly 9 in 10 of those prescriptions were paid for out of pocket, rather than through insurance.Most of the prescriptions so far have been for the lowest dose, also known as the starter dose, which is typically used by people just beginning weight loss treatment.On a call with investors Wednesday, David Moore, president of Novo Nordisk U.S., said early uptake of the Wegovy pill was more than twice that of any previous weight loss drug launch in the United States.“Most prescriptions appear to be patients new to these medications,” he said.The numbers offer the first glimpse of demand for a GLP-1 weight loss pill. The Food and Drug Administration approved the Wegovy pill in late December.The demand comes asthe GLP-1 market grows more crowdedThe Wegovy pill comes at a much lower price than the injectable version. The starter dose costs $149 a month for people paying in c
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]CNBC
- Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do [Seeking Alpha]Seeking Alpha
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance]Yahoo! Finance
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk Q4: Slumping Due To Weak Guidance [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/4/26 - Form IRANNOTICE
- 2/4/26 - Form 20-F
- 2/4/26 - Form 6-K
- NVO's page on the SEC website